Article Versions Notes

Kaidun P, Holzmayer SJ, Greiner SM, Seller A, Tegeler CM, Hagelstein I, Mauermann J, Engler T, Koch A, Hartkopf AD, et al. Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer. International Journal of Molecular Sciences. 2023; 24(17):13156. https://doi.org/10.3390/ijms241713156

Kaidun, Polina, Samuel J. Holzmayer, Sarah M. Greiner, Anna Seller, Christian M. Tegeler, Ilona Hagelstein, Jonas Mauermann, Tobias Engler, André Koch, Andreas D. Hartkopf, and et al. 2023. "Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer" International Journal of Molecular Sciences 24, no. 17: 13156. https://doi.org/10.3390/ijms241713156

Kaidun, P., Holzmayer, S. J., Greiner, S. M., Seller, A., Tegeler, C. M., Hagelstein, I., Mauermann, J., Engler, T., Koch, A., Hartkopf, A. D., Salih, H. R., & Märklin, M. (2023). Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer. International Journal of Molecular Sciences, 24(17), 13156. https://doi.org/10.3390/ijms241713156